While symptoms of Crohn’s disease, such as abdominal pain, diarrhea, fatigue, and bloating can disrupt daily life, they don’t ...

Patients with moderate to severe Crohn’s disease who did not achieve clinical response to IV induction with Skyrizi ...

Guselkumab is the first and only interleukin-23 inhibitor that offers both subcutaneous and intravenous induction options for ...

A plant-based diet made up of mainly nutrient-dense plant foods, or an equally healthy omnivorous diet may help reduce the ...

A 21-year-old fought hard against his colorectal cancer and spoke with News 3 about his second chance at life.

A new study suggests AI can predict premature death among people who have inflammatory bowel disease, also known as Crohn's ...

A gastrointestinal doctor reveals the mistakes you should avoid if you want to lower your risk of colon cancer.

New study shows that dysfunction of protective immune cells in GI tract may contribute to onset of inflammation in Crohn's disease.

A research team led by Mount Sinai has uncovered mechanisms of abnormal immune cell function that may lead to Crohn's disease ...

March is national Colorectal Cancer Awareness Month, and area health care professionals are committed to education and prevention. According to a Bassett Healthcare Network media release, March is “a ...

The FDA has approved guselkumab (Tremfya) as the first IL-23 inhibitor offering both subcutaneous and intravenous induction ...

The FDA expanded the approval of guselkumab (Tremfya) to include treatment of moderately to severely active Crohn's disease, drugmaker Johnson & Johnson announced on Thursday. An interleukin (IL)-23 ...